Prakriti-Based Personalized Medicine: How Your Constitution Predicts Drug Response

Two people can receive the same medicine and have very different results. Age, kidney and liver function, other medicines, diet, adherence, disease severity, and inherited variation can all affect efficacy and toxicity. Modern pharmacogenomics studies specific gene–drug relationships. Ayurgenomics asks a different but related research question: do the constitutional phenotypes called Prakriti correspond to reproducible molecular differences that might eventually add useful information to individualized care?

That question is scientifically legitimate, but the clinical claims often made from it are much stronger than the evidence. The studies reviewed here do not show that a Pitta-predominant patient needs a higher antihypertensive dose, that a Kapha-predominant patient clears medicines slowly, or that Vata, Pitta, and Kapha can substitute for a pharmacogenetic test. The available literature consists mainly of cross-sectional studies of healthy volunteers, molecular association studies, and reviews.

Peer-reviewed work has appeared in the Journal of Translational Medicine, Proceedings of the National Academy of Sciences, Scientific Reports, Evidence-Based Complementary and Alternative Medicine, and the Journal of Ayurveda and Integrative Medicine. An ACS Chemical Biology article discussed Ayurgenomics as a framework for stratified medicine, but it was not a clinical dosing trial.

Disclosure: Ayurgenomics remains an exploratory research field. Do not change the dose, timing, or choice of any prescribed medicine on the basis of Prakriti. Medication decisions should be made with a qualified physician; Ayurvedic treatment should be supervised by a properly qualified Ayurvedic practitioner, especially when herbs and prescription medicines are combined.

The Ayurgenomics Framework: What Researchers Are Actually Studying

In classical Ayurveda, Prakriti is the relatively stable constitution established from the beginning of life, while a person’s current doshic disturbance is assessed separately. Charaka Samhita, Vimana Sthana 8/95 describes factors associated with the formation of constitution, and 8/96–99 describes characteristics of Kapha-, Pitta-, and Vata-predominant constitutions. Modern Ayurgenomics does not directly prove doshas as molecular entities; it tests whether people classified by an Ayurvedic phenotype show reproducible differences in measurable biological variables.

The most defensible hypothesis is therefore limited: a carefully assessed phenotype may enrich a study group for certain genetic, transcriptomic, biochemical, epigenetic, or metabolic features. Demonstrating such enrichment would not by itself prove that Prakriti predicts response to a medicine. That requires prospective pharmacokinetic or clinical-outcome studies in which drug exposure, therapeutic response, and adverse events are measured directly.

A foundational 2008 study led by Bhavana Prasher and Mitali Mukerji screened 850 volunteers and ultimately included 96 unrelated, ethnically matched healthy participants with predominant Vata, Pitta, or Kapha phenotypes. Contrary to a frequently repeated description, the final sample was not 262 men: it included 48 men and 48 women. The investigators reported group differences in selected biochemical and hematological measures and in gene-expression categories related to processes such as transport, immune response, cyclin-dependent kinase regulation, and blood coagulation. The work was exploratory, used extreme constitutional types, and did not test any drug.

Genome-Wide Variation: What the 2015 Study Found

The 2015 Scientific Reports study is also often misquoted. Researchers assessed 3,416 healthy men aged 20–30, but genome-wide SNP analysis was performed on 262 men with strongly predominant and concordantly classified Prakriti: 94 Vata, 75 Pitta, and 93 Kapha. After permutation testing, 52 SNPs differed among the groups at the study’s stated significance threshold, and principal-component analysis separated the selected study participants.

The authors also applied a statistical model to 297 Indian population samples of known ancestry. Only 37 of those samples satisfied the model’s criteria and were projected into the proposed Prakriti clusters. This was a limited secondary analysis, not independent clinical validation of a Prakriti diagnostic test. The paper further reported Pitta-associated markers in and around PGM1, a gene involved in carbohydrate metabolism.

Importantly, the study did not report that Pitta was enriched for CYP3A4 or CYP2C9 variants, that Kapha was defined by slow drug clearance, or that Vata carried catecholamine-pathway variants that predict psychoactive-drug sensitivity. Those specific statements are not supported by the paper and should not be used in patient counseling.

CYP2C19 and Prakriti: The Main Direct Pharmacogenomic Association

The clearest published Prakriti–drug-metabolism association comes from a study of CYP2C19, published online in 2009 and in its final journal volume in 2011. Investigators screened 489 healthy volunteers and recruited 132 unrelated participants with predominant Prakriti: 63 Kapha, 43 Pitta, and 26 Vata. The sample included both men and women.

Using the alleles tested in that study, the authors classified 91% of the Pitta group as “extensive metabolizers,” while the genotype category labeled “poor metabolizer” occurred in 31% of Kapha, 12% of Vata, and 9% of Pitta participants. The CYP2C19*2/*3 genotype was reported only in Kapha and was associated with Kapha in the study, with a reported odds ratio of 3.5 and a p value of .008.

This result is noteworthy, but its boundaries matter. The researchers studied genotype distribution; they did not administer a CYP2C19 substrate, measure plasma drug concentrations, compare therapeutic outcomes, or establish safe doses for any Prakriti. Allele coverage and metabolizer terminology have also evolved since the study. It is therefore evidence for a possible association requiring replication, not evidence that all Kapha individuals are slow metabolizers or that Prakriti can replace clinical CYP2C19 genotyping.

A Corrected Evidence Map

The strongest verified studies support molecular correlation, not Prakriti-based prescribing. The following table separates what each study observed from the clinical conclusions it cannot establish.

None of these studies was a randomized medication trial, and none produced a clinically validated dosing algorithm. A molecular difference can be real yet still be too small, too population-specific, or too poorly replicated to guide treatment for an individual.

What the Research Demonstrates—and What It Does Not

The evidence supports a modest conclusion: strongly selected Prakriti groups have shown differences in some molecular and biochemical measurements. It does not yet show that a patient’s Prakriti reliably predicts the concentration, benefit, or toxicity of a prescribed drug. Several methodological issues explain why the gap remains large.

Study Populations and Replication

Samples have generally been small after strict phenotypic selection, and some influential studies included only young Indian men or focused on particular Indian ancestry groups. The 2008 study included women, but sex-specific expression differences and greater within-group variability were also observed. Robust clinical use would require independent replication across sexes, ages, regions, ancestries, disease states, and treatment settings.

Assessment Reliability

Prakriti classification is not yet measured by one universally accepted research instrument. A 2025 critical review identified 64 distinct assessment tools used from 1987 through 2024; only 20 had undergone any validation or reliability testing, and only two met seven of the nine criteria used by the reviewers. When studies use different questionnaires, scoring rules, software, or physician judgments, apparently similar labels may not define equivalent groups.

Prakriti, Vikriti, and Confounding

Classical Prakriti should not be described as something that changes with each season, diet, or current illness. Those factors may alter present symptoms, doshic imbalance, laboratory values, gene expression, or how constitution is perceived during assessment. Research must therefore distinguish stable constitutional classification from current vikriti and control for ancestry, body composition, diet, sleep, medications, geography, socioeconomic conditions, and other environmental influences.

Association Is Not Prediction

A statistically different allele frequency between groups does not mean that every person in a group carries the allele, and it does not show that the allele changes a clinical outcome. A useful predictor must add reproducible information beyond established factors, be tested in an external population, and improve a decision such as drug choice, starting dose, monitoring, or avoidance. Existing Ayurgenomics studies have not yet crossed that threshold.

Metabolomics and Other Molecular Correlates

A study published online in 2017 and in print in 2018 in the Journal of Ayurveda and Integrative Medicine examined fasting plasma from 38 healthy men and reported differences in inferred metabolic pathways among Prakriti groups, including branched-chain amino-acid and glycerolipid processes in Pitta and catecholamine, arachidonic-acid, and hydrogen-peroxide processes in Vata.

That small untargeted metabolomics study did not establish that Kapha patients respond differently to NSAIDs or corticosteroids, that Pitta patients clear protein-bound medicines faster, or that any group has a predictable inflammatory baseline. Such clinical inferences would require targeted assays, replication, drug-exposure measurements, and patient outcomes.

A separate PNAS study linked EGLN1 variation, constitution-based stratification, and high-altitude adaptation. This supports the broader idea that detailed phenotyping can help reveal biological associations. It does not validate a universal relationship between dosha and drug metabolism.

Established Pharmacogenomics Must Remain Separate

Conventional pharmacogenomics already contains well-studied gene–drug pairs, but these should not be retrofitted onto Prakriti without direct evidence. Clinical Pharmacogenetics Implementation Consortium guidelines explain how available genotype results may be used for particular medicines; they do not endorse Vata, Pitta, or Kapha as surrogate genotypes.

Warfarin

Warfarin dose requirements can be influenced by variants in CYP2C9, VKORC1, and CYP4F2, together with clinical factors. Current CPIC guidance addresses those measured genotypes. No verified study reviewed here shows that Kapha is enriched for reduced-function CYP2C9 variants or that Prakriti predicts bleeding on warfarin. Anticoagulant dosing must never be altered from constitutional appearance.

Codeine

CYP2D6 genotype can affect conversion of codeine to morphine, and CPIC provides recommendations for known CYP2D6 phenotypes. The Ayurgenomics studies reviewed here do not establish a distribution of CYP2D6 phenotypes by Prakriti. A proposed Vata sensitivity to codeine or psychoactive medicines is therefore unverified.

Statins

The current CPIC statin guideline focuses on SLCO1B1, ABCG2, and CYP2C9 in relation to statin exposure and musculoskeletal symptoms. It does not describe Pitta as a rapid CYP3A4 phenotype or Kapha as a slow-clearance phenotype. Body build or a dosha label cannot be used to estimate statin myopathy risk.

Clinical Implications: What Practitioners Can and Cannot Do Today

Clinicians should not use Prakriti to determine prescription-drug doses. It may remain part of a traditional Ayurvedic assessment, but it is not a validated substitute for medication history, renal and hepatic assessment, therapeutic drug monitoring, evidence-based pharmacogenetic testing, or disease-specific prescribing guidance.

1. Do not infer metabolizer status from dosha. A Pitta label does not prove rapid clearance, and a Kapha label does not prove poor metabolism or accumulation.
2. Use validated gene–drug guidance when relevant. Where a recognized guideline exists, decisions should be based on the actual genotype or phenotype and the patient’s clinical circumstances.
3. Review herb–drug combinations individually. Interaction risk depends on the herb, preparation, dose, product quality, medicine, and patient—not on an unvalidated constitutional shortcut.
4. Keep Ayurvedic reasoning within its evidence and scope. A qualified practitioner may consider Prakriti alongside agni, current doshic imbalance, strength, age, season, diet, and disease, but this does not authorize changing a pharmaceutical dose.

Anyone taking anticoagulants, antiplatelet medicines, immunosuppressants, anticonvulsants, psychiatric medicines, chemotherapy, or other narrow-therapeutic-index drugs should seek medical advice before adding herbal products. New fatigue, bleeding, jaundice, rash, fainting, severe gastrointestinal symptoms, or other suspected adverse effects require prompt clinical evaluation rather than dosha-based self-correction.

The Road Ahead: What Research Is Needed

Ayurgenomics could become more informative if future studies move from retrospective molecular association to prospective clinical testing. The essential question is not merely whether groups differ, but whether Prakriti adds accurate, reproducible, and clinically useful prediction after known genetic and clinical variables are included.

• Pre-registered, adequately powered studies using clearly specified and independently validated Prakriti instruments
• Direct pharmacokinetic testing with defined probe drugs, measured concentrations, and prespecified outcomes
• Replication in women and men across ages, ancestries, regions, body compositions, and disease populations
• Parallel measurement of relevant genotypes, liver and kidney function, diet, co-medication, adherence, and environmental factors
• Separation of innate Prakriti from current vikriti and temporary disease-related phenotypes
• External validation showing that Prakriti improves prediction beyond ordinary clinical assessment and established pharmacogenomics
• Prospective evaluation of adverse drug reactions, therapeutic response, and cost-effectiveness before clinical implementation

Until those requirements are met, Ayurgenomics is best understood as a promising phenotype-to-biology research program, not a bedside dosing system. Its value may lie in generating hypotheses and refining cohorts for investigation, but clinical utility must be demonstrated rather than assumed.

A Note on Traditional Ayurveda

Classical Ayurveda does emphasize individualized examination. In Charaka Samhita, Prakriti is one relevant feature of the patient, not the sole basis of treatment. The physician is expected to assess the person, the disorder, strength, current imbalance, suitability, diet, environment, and the properties of the proposed intervention. The Prakriti passages are in Vimana Sthana 8/95–99, not Sharira Sthana Chapter 4.

This individualized orientation is conceptually compatible with the goal of precision medicine, but conceptual similarity is not scientific equivalence. Pharmacogenomics links particular variants to particular drugs under defined conditions; Prakriti is a multidimensional clinical construct. Respecting both traditions requires keeping those categories distinct until direct evidence justifies a bridge.

Educational content cannot replace personal medical care. Consult a qualified physician before changing any medicine and a qualified Ayurvedic practitioner for individualized Ayurvedic assessment. Seek urgent care for serious or rapidly worsening symptoms.

References

1. Link (link.springer.com)
2. Charaka Samhita — Prakriti
3. Charaka Samhita — Rogabhishagjitiya Vimana
4. Nature (nature.com)
5. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed
6. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed Central
7. Pubs (pubs.acs.org)
8. Pnas (pnas.org)
9. Plasma metabolomics reveal the correlation of metabolic pathways and Prakritis of humans (2018), PubMed
10. Plasma metabolomics reveal the correlation of metabolic pathways and Prakritis of humans (2018), PubMed Central
11. Frontiersin (frontiersin.org)
12. Cpicpgx (cpicpgx.org)
13. Cpicpgx (cpicpgx.org)
14. Cpicpgx (cpicpgx.org)